Inhibitors of protein kinases

A method for treating a leukemia comprising the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound having the formula I

• or a pharmaceutically acceptable salt thereof, wherein:
• D1 is cyclopropyl;
• R1 is selected from the group consisting of H, C1-8 alkyl, amino, aminocarbonyl, hydroxyl, C1-8 alkoxy, C1-8 haloalkyl, C2-8 alkenyl, C2-8 alkynyl, oxo, cyano, C1-8 alkoxycarbonyl, C3-8 cycloalkyl, aryl and heterocyclyl;
• and each heterocyclyl is optionally substituted with from 1 to 4 substituents selected from the group consisting of C1-8 alkyl, halo, oxo, amino, C1-8alkoxy, C1-8alkylcarbonyl, arylC1-8 alkoxycarbonyl, aminocarbonyl, arylC1-8 alkylenecarbonyl and C1-8 alkylsulfonyl
• Y1 is phenyl optionally substituted with from 1 to 3 R4a substituents, independently selected from the group consisting of C1-8alkyl, C1-8alkoxyC1-8alkyl, aminocarbonyl-, hydroxyl, halogen, hydroxy, C1-8alkoxy and C1-8alkylsulfonyl;
• R2 is piperazinyl;
• and wherein R2 is further substituted with from 1 to 2 R4c substituents, independently selected from the group consisting of C1-8alkylcarbonyl and C1-8alkylsulfonyl.